Akso Health Group (HX) Stock Competitors & Peer Comparison
See (HX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HX | $2.24 | -4.27% | 53.4M | -1.84 | -$1.22 | N/A |
| MCK | $750.63 | -3.74% | 87.9B | 19.54 | $38.41 | +0.44% |
| COR | $271.83 | -1.90% | 52.9B | 20.81 | $13.06 | +0.86% |
| CAH | $221.77 | -1.99% | 51.9B | 33.91 | $6.54 | +0.92% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $79.92 | -0.06% | 9.1B | 24.15 | $3.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| GRDN | $42.41 | -2.28% | 2.7B | 50.49 | $0.84 | N/A |
| PBH | $46.97 | +1.80% | 2.2B | 12.01 | $3.91 | N/A |
| ACH | $3.23 | +2.22% | 247.4M | -2.36 | -$1.37 | N/A |
Stock Comparison
HX vs MCK Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, MCK has a market cap of 87.9B. Regarding current trading prices, HX is priced at $2.24, while MCK trades at $750.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas MCK's P/E ratio is 19.54. In terms of profitability, HX's ROE is -1.07%, compared to MCK's ROE of -2.65%. Regarding short-term risk, HX is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check MCK's competition here
HX vs COR Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, COR has a market cap of 52.9B. Regarding current trading prices, HX is priced at $2.24, while COR trades at $271.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas COR's P/E ratio is 20.81. In terms of profitability, HX's ROE is -1.07%, compared to COR's ROE of +1.16%. Regarding short-term risk, HX is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check COR's competition here
HX vs CAH Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CAH has a market cap of 51.9B. Regarding current trading prices, HX is priced at $2.24, while CAH trades at $221.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CAH's P/E ratio is 33.91. In terms of profitability, HX's ROE is -1.07%, compared to CAH's ROE of -0.56%. Regarding short-term risk, HX is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check CAH's competition here
HX vs ABC Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, HX is priced at $2.24, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ABC's P/E ratio is 21.92. In terms of profitability, HX's ROE is -1.07%, compared to ABC's ROE of +1.16%. Regarding short-term risk, HX is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check ABC's competition here
HX vs HSIC Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, HSIC has a market cap of 9.1B. Regarding current trading prices, HX is priced at $2.24, while HSIC trades at $79.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas HSIC's P/E ratio is 24.15. In terms of profitability, HX's ROE is -1.07%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, HX is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check HSIC's competition here
HX vs PDCO Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, HX is priced at $2.24, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HX's ROE is -1.07%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, HX is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check PDCO's competition here
HX vs GRDN Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, GRDN has a market cap of 2.7B. Regarding current trading prices, HX is priced at $2.24, while GRDN trades at $42.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas GRDN's P/E ratio is 50.49. In terms of profitability, HX's ROE is -1.07%, compared to GRDN's ROE of +0.27%. Regarding short-term risk, HX is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check GRDN's competition here
HX vs PBH Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PBH has a market cap of 2.2B. Regarding current trading prices, HX is priced at $2.24, while PBH trades at $46.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PBH's P/E ratio is 12.01. In terms of profitability, HX's ROE is -1.07%, compared to PBH's ROE of +0.10%. Regarding short-term risk, HX is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check PBH's competition here
HX vs ACH Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ACH has a market cap of 247.4M. Regarding current trading prices, HX is priced at $2.24, while ACH trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ACH's P/E ratio is -2.36. In terms of profitability, HX's ROE is -1.07%, compared to ACH's ROE of +2.65%. Regarding short-term risk, HX is more volatile compared to ACH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check ACH's competition here
HX vs OMI Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, HX is priced at $2.24, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas OMI's P/E ratio is -0.47. In terms of profitability, HX's ROE is -1.07%, compared to OMI's ROE of +2.69%. Regarding short-term risk, HX is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for HX.Check OMI's competition here
HX vs GEG Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, GEG has a market cap of 86.5M. Regarding current trading prices, HX is priced at $2.24, while GEG trades at $2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas GEG's P/E ratio is -3.45. In terms of profitability, HX's ROE is -1.07%, compared to GEG's ROE of -0.38%. Regarding short-term risk, HX is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for HX.Check GEG's competition here
HX vs WGRX Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, WGRX has a market cap of 8.5M. Regarding current trading prices, HX is priced at $2.24, while WGRX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas WGRX's P/E ratio is -0.08. In terms of profitability, HX's ROE is -1.07%, compared to WGRX's ROE of +15.45%. Regarding short-term risk, HX is more volatile compared to WGRX. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check WGRX's competition here
HX vs ZYXI Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, HX is priced at $2.24, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, HX's ROE is -1.07%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, HX is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check ZYXI's competition here
HX vs SNYR Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, SNYR has a market cap of 2.5M. Regarding current trading prices, HX is priced at $2.24, while SNYR trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas SNYR's P/E ratio is -0.15. In terms of profitability, HX's ROE is -1.07%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, HX is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for HX.Check SNYR's competition here
HX vs MEHA Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, MEHA has a market cap of 129.5K. Regarding current trading prices, HX is priced at $2.24, while MEHA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas MEHA's P/E ratio is -0.06. In terms of profitability, HX's ROE is -1.07%, compared to MEHA's ROE of +11.59%. Regarding short-term risk, HX is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for HX.Check MEHA's competition here
HX vs RDGT Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, RDGT has a market cap of 364. Regarding current trading prices, HX is priced at $2.24, while RDGT trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas RDGT's P/E ratio is -0.03. In terms of profitability, HX's ROE is -1.07%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, HX is more volatile compared to RDGT. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check RDGT's competition here
HX vs CVET Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CVET has a market cap of 0. Regarding current trading prices, HX is priced at $2.24, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CVET's P/E ratio is -69.97. In terms of profitability, HX's ROE is -1.07%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HX is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check CVET's competition here